Appeals Court Affirms Dismissal of Lipitor Diabetes Litigation

The U.S. Court of Appeals for the Fourth Circuit has affirmed the controversial decision of a federal judge to dismiss all Lipitor diabetes cases, finding that there was no reversible error in an opinion published this week. 

More than 3,000 women nationwide have filed Lipitor lawsuits against Pfizer in recent years, alleging that the drug maker failed to adequately warn that side effects of the popular cholesterol drug may increase the risk of diabetes.

Given similar questions of fact and law presented in the complaints, cases filed throughout the federal court system were consolidated as part of a multidistrict litigation (MDL) before U.S. District Judge Richard Gergel in the District of South Carolina, for coordinated discovery and to avoid conflicting rulings during pretrial proceedings.

Did You Know?

Ticketmaster Data Breach Impacts Millions of Customers

A massive Ticketmaster data breach exposed the names, addresses, phone numbers, credit card numbers and other personal information of more than 560 million customers, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

In January 2017, Judge Gergel issued an order excluding certain expert witness testimony proposed by the plaintiffs, and granted a motion for summary judgment filed by the drug maker, who argued that the plaintiffs were unable to prove their case without the expert opinion.

Plaintiffs appealed the decision, and an opinion (PDF) was issued by a three-judge panel on June 12, upholding the lower court’s decision.

“These cases involve difficult questions of mathematics and science, wrapped in a complex form of mass litigation. The district court here had to make a number of decisions pursuant to both its ‘gatekeeper’ role imposed by Daubert, as well as its supervisory role as the transferee court in a large multidistrict litigation,” the panel determined. “The court discharged those duties meticulously and thoughtfully throughout the litigation, including performing careful review of the many expert reports, affording experts the opportunity to amend and revise those reports to ensure their opinions were fully considered, and, after ultimately excluding much of the plaintiffs’ expert testimony, allowing them to come forward with any additional evidence that could salvage what remained of their cases before rendering a final decision.”

It is unclear whether plaintiffs will attempt to appeal the Fourth Circuit’s decision, which would require the U.S. Supreme Court to agree to consider the issue.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

AFFF Ulcerative Colitis Lawsuit Filed Over Contaminated Water in Colorado Springs
AFFF Ulcerative Colitis Lawsuit Filed Over Contaminated Water in Colorado Springs (Posted today)

Lawsuit blames PFAS manufacturers for failing to prevent water contamination by their chemicals, or warn municipalities and the public about the potential risks of ulcerative colitis and other diseases as a result of exposure.

Port Catheter Infection Lawsuits Over Bard PowerPort Devices Claim Faulty Design Promotes Colonization of Bacteria
Port Catheter Infection Lawsuits Over Bard PowerPort Devices Claim Faulty Design Promotes Colonization of Bacteria (Posted yesterday)

Hundreds of currently pending Bard PowerPort lawsuits over infections, fractures and migration injuries were consolidated into a multidistrict litigation (MDL), but now even more claims present similar allegations that the implantable port catheter system has dangerous design defects that were not adequately disclosed by the manufacturer.

Johnson & Johnson Increases Talcum Powder Settlement Offer by $1.1B: Reuters
Johnson & Johnson Increases Talcum Powder Settlement Offer by $1.1B: Reuters (Posted yesterday)

A recent report suggests that Johnson & Johnson is offering an additional $1.1 billion to settle talcum powder lawsuits, as part of a proposed $9 billion deal that would resolve all ovarian cancer claims as part of a third bankruptcy filing by the manufacturer.